Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.17
+1.9%
$2.22
$1.63
$5.04
$11.24M0.82290,344 shs13,135 shs
Bright Green Co. stock logo
BGXX
Bright Green
$0.05
$0.03
$0.54
$11.47M-0.26360,154 shs25,935 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$4.17
+15.7%
$0.23
$2.85
$52.20
$378.52M0.1884,871 shs517,843 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.57
-3.2%
$1.00
$0.55
$737.44
$2.08M0.77767,122 shs236,882 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
+1.88%+0.46%-18.11%-17.18%-51.02%
Bright Green Co. stock logo
BGXX
Bright Green
0.00%0.00%0.00%+25.00%-84.21%
IN8bio, Inc. stock logo
INAB
IN8bio
+3,372.11%+2,729.04%+2,458.28%+1,588.94%+204.38%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-3.22%-27.45%-34.70%-70.10%-99.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCardia, Inc. stock logo
BCDA
BioCardia
3.473 of 5 stars
3.85.00.00.02.22.50.6
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
2.4425 of 5 stars
3.53.00.00.01.12.50.6
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
1.6697 of 5 stars
3.02.00.00.02.20.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,052.07% Upside
Bright Green Co. stock logo
BGXX
Bright Green
0.00
N/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
3.00
Buy$6.0043.88% Upside
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0061,508.87% Upside

Current Analyst Ratings Breakdown

Latest WINT, BGXX, BCDA, and INAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2025
IN8bio, Inc. stock logo
INAB
IN8bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $6.00
(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K3,745.42N/AN/A($1.11) per share-1.95
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/A$0.06 per shareN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/A$0.58 per shareN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$10.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)
Bright Green Co. stock logo
BGXX
Bright Green
-$13.13M-$0.06N/AN/AN/AN/A-88.37%-55.30%N/A
IN8bio, Inc. stock logo
INAB
IN8bio
-$30.01M-$0.45N/AN/AN/AN/A-197.15%-130.48%8/14/2025 (Estimated)
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%8/18/2025 (Estimated)

Latest WINT, BGXX, BCDA, and INAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/8/2025Q1 2025
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.06-$0.07-$0.01-$0.07N/AN/A
3/26/2025Q4 2024
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million
3/13/2025Q4 2024
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.07-$0.04+$0.03-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Bright Green Co. stock logo
BGXX
Bright Green
N/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
1.78
1.78
Bright Green Co. stock logo
BGXX
Bright Green
N/A
0.01
0.01
IN8bio, Inc. stock logo
INAB
IN8bio
0.05
1.84
1.84
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.27
0.27

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Bright Green Co. stock logo
BGXX
Bright Green
7.83%
IN8bio, Inc. stock logo
INAB
IN8bio
92.05%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Bright Green Co. stock logo
BGXX
Bright Green
62.55%
IN8bio, Inc. stock logo
INAB
IN8bio
15.50%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.18 million3.67 millionOptionable
Bright Green Co. stock logo
BGXX
Bright Green
2191.17 million71.59 millionNo Data
IN8bio, Inc. stock logo
INAB
IN8bio
2090.77 million61.25 millionNot Optionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million11.01 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.17 +0.04 (+1.88%)
Closing price 06/6/2025 03:55 PM Eastern
Extended Trading
$2.18 +0.02 (+0.69%)
As of 06/6/2025 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Bright Green stock logo

Bright Green NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

IN8bio stock logo

IN8bio NASDAQ:INAB

$4.17 +0.57 (+15.74%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$3.73 -0.44 (-10.46%)
As of 06/6/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.57 -0.02 (-3.22%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.56 -0.01 (-0.90%)
As of 06/6/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.